enGene Therapeutics Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
1.765
+0.005 (0.28%)
Jul 31, 2026, 1:52 PM EDT - Market open
enGene Therapeutics Employees
As of October 31, 2025, enGene Therapeutics had 82 total employees, including 81 full-time and 1 part-time employees. The number of employees increased by 25 or 43.86% compared to the previous year.
Employees
82
Change (1Y)
25
Growth (1Y)
43.86%
Revenue / Employee
n/a
Profits / Employee
-$1,546,951
Market Cap
118.24M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Oct 31, 2025 | 82 | 25 | 43.86% | 81 | 1 |
| Oct 31, 2024 | 57 | 24 | 72.73% | 56 | 1 |
| Oct 31, 2023 | 33 | - | - | 31 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Nautilus Biotechnology | 127 |
| Seer, Inc. | 124 |
| Fractyl Health | 100 |
| Rani Therapeutics Holdings | 71 |
| PepGen | 59 |
| Vivani Medical | 42 |
| Cue Biopharma | 29 |
| Spruce Biosciences | 14 |
ENGN News
- 15 days ago - enGene announces changes to board, appoints Heffernan as Chairman - TheFly
- 15 days ago - enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones - Business Wire
- 16 days ago - Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman - GlobeNewsWire
- 4 weeks ago - enGene Therapeutics Slides: Corporate presentation - Filings
- 6 weeks ago - enGene downgraded to Underweight from Equal Weight at Morgan Stanley - TheFly
- 6 weeks ago - enGene price target lowered to $4 from $6 at H.C. Wainwright - TheFly
- 6 weeks ago - enGene implements plan to reduce workforce by 50% - TheFly
- 6 weeks ago - enGene Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire